Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy

Journal of Urology

Volumn 188, Issue 5, 2012, Pages 1761-1766

  Boorjian, Stephen A ^a   Tollefson, Matthew K ^a   Thompson, R Houston ^a   Rangel, Laureano J ^a   Bergstralh, Eric J ^a   Karnes, R Jeffrey ^a  

^a MAYO CLINIC   (United States)

Author keywords

adjuvant; local; neoplasm recurrence; prostate; prostate specific antigen; prostatic neoplasms; radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

AGED; DISEASE PROGRESSION; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84867404108     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2012.07.037     Document Type: Article

References (30)

1. J.F. Ward, M.L. Blute, J. Slezak The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy J Urol 170 2003 1872
2. M. Han, A.W. Partin, C.R. Pound Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience Urol Clin North Am 28 2001 555
3. K.A. Roehl, M. Han, C.G. Ramos Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 172 2004 910
4. P.K. Agarwal, N. Sadetsky, B.R. Konety Treatment failure after primary and salvage therapy for prostate cancer Cancer 112 2008 307
5. S.J. Freedland, E.B. Humphreys, L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433
6. C.R. Pound, A.W. Partin, M.A. Eisenberger Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591
7. P. Zhou, M.H. Chen, D. McLeod Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Clin Oncol 23 2005 6992
8. S.A. Boorjian, R.H. Thompson, M.K. Tollefson Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893
9. P.C. Albertsen, J.A. Hanley, D.F. Gleason Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer JAMA 280 1998 975
10. F.J. Bianco Jr, P.T. Scardino, J.A. Eastham Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta") Urology 66 2005 83
11. S.S. Mehta, D.P. Lubeck, N. Sadetsky Patterns of secondary cancer treatment for biochemical failure following radical prostatectomy: data from CaPSURE J Urol 171 2004 215
12. G.D. Grossfeld, D.M. Stier, S.C. Flanders Use of second treatment following definitive local therapy for prostate cancer: data from the CaPSURE database J Urol 160 1998 1404
13. M. Bolla, H. van Poppel, L. Collette Postoperative radiotherapy after radical prostatectomy: a randomized controlled trial (EORTC trial 22911) Lancet 366 2005 572
14. I.M. Thompson, C.M. Tangen, J. Paradelo Adjuvant radiotherapy for pathologically advanced prostate cancer JAMA 296 2006 2329
15. T. Wiegel, D. Bottke, U. Steiner Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924
16. I.M. Thompson, C.M. Tangen, J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956
17. J.W. Moul Prostate specific antigen only progression of prostate cancer J Urol 163 2000 1632
18. C.L. Amling, E.J. Bergstralh, M.L. Blute Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165 2001 1146
19. S.G. Roberts, M.L. Blute, E.J. Bergstralh PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer Mayo Clin Proc 76 2001 576
20. J.P. Fine, R.J. Gray A proportional hazards model for the sub distribution of a competing risk J Am Stat Assoc 94 1999 496
21. S.J. Freedland, E.B. Humphreys, L.A. Mangold Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality J Urol 176 2006 1404
22. A.V. D'Amico, J.W. Moul, P.R. Carroll Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376
23. S.J. Freedland, E.B. Humphreys, L.A. Mangold Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality J Clin Oncol 25 2007 1765
24. D.M. Moreira, L.L. Bañez, J.C. Presti Jr Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database BJU Int 105 2009 28
25. P. Rigatti, N. Suardi, A. Briganti Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography Eur Urol 60 2011 935
26. J.W. Moul, H. Wu, L. Sun Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2004 1141
27. S.A. Siddiqui, S.A. Boorjian, B. Inman Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study J Urol 179 2008 1830
28. A. Briganti, R.J. Karnes, L.F. Da Pozzo Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis Eur Urol 59 2011 832
29. S.A. Boorjian, R.H. Thompson, S. Siddiqui Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era J Urol 178 2007 864
30. E.M. Messing, J. Manola, J. Yao Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472